Institute of Diabetes, Obesity and Metabolism and School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania.
Department of Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania.
Diabetes Obes Metab. 2022 Jun;24(6):1010-1020. doi: 10.1111/dom.14663. Epub 2022 Mar 7.
To evaluate whether the potent hypophagic and weight-suppressive effects of growth differentiation factor-15 (GDF15) and semaglutide combined would be a more efficacious antiobesity treatment than either treatment alone by examining whether the neural and behavioural mechanisms contributing to their anorectic effects were common or disparate.
MATERIALS/METHODS: Three mechanisms were investigated to determine how GDF15 and semaglutide induce anorexia: the potentiation of the intake suppression by gastrointestinal satiation signals; the reduction in motivation to feed; and the induction of visceral malaise. We then compared the effects of short-term, combined GDF15 and semaglutide treatment on weight loss to the individual treatments. Rat pharmaco-behavioural experiments assessed whether GDF15 or semaglutide added to the satiating effects of orally gavaged food and exogenous cholecystokinin (CCK). A progressive ratio operant paradigm was used to examine whether GDF15 or semaglutide reduced feeding motivation. Pica behaviour (ie, kaolin intake) and conditioned affective food aversion testing were used to evaluate visceral malaise. Additionally, fibre photometry studies were conducted in agouti-related protein (AgRP)-Cre mice to examine whether GDF15 or semaglutide, alone or in combination with CCK, modulate calcium signalling in hypothalamic AgRP neurons.
Semaglutide reduced food intake by amplifying the feeding-inhibitory effect of CCK or ingested food, inhibited the activity of AgRP neurons when combined with CCK, reduced feeding motivation and induced malaise. GDF15 induced visceral malaise but, strikingly, did not affect feeding motivation, the satiating effect of ingested food or CCK signal processing. Combined GDF15 and semaglutide treatment produced greater food intake and body weight suppression than did either treatment alone, without enhancing malaise.
GDF15 and semaglutide reduce food intake and body weight through largely distinct processes that produce greater weight loss and feeding suppression when combined.
通过研究导致其厌食效果的神经和行为机制是共同的还是不同的,评估生长分化因子 15 (GDF15) 和司美格鲁肽联合使用的强大的食欲抑制和体重抑制作用是否比单独使用任何一种治疗方法更有效。
材料/方法:为了确定 GDF15 和司美格鲁肽如何引起厌食,我们研究了三种机制:增强胃肠道饱腹感信号对摄食的抑制作用;降低进食动机;以及诱导内脏不适。然后,我们比较了短期联合 GDF15 和司美格鲁肽治疗对体重减轻的效果与单独治疗的效果。大鼠药物行为实验评估了 GDF15 或司美格鲁肽是否会增加口服灌胃食物和外源性胆囊收缩素 (CCK) 的饱腹感效应。使用递增比例操作范式来检查 GDF15 或司美格鲁肽是否降低了进食动机。食癖行为(即高岭土摄入)和条件性食物厌恶测试用于评估内脏不适。此外,在 agouti 相关蛋白 (AgRP)-Cre 小鼠中进行光纤光度测定研究,以检查 GDF15 或司美格鲁肽,单独或与 CCK 联合使用,是否调节下丘脑 AgRP 神经元中的钙信号。
司美格鲁肽通过放大 CCK 或摄入食物的摄食抑制作用来减少食物摄入,与 CCK 联合使用时抑制 AgRP 神经元的活动,降低进食动机并引起不适。GDF15 引起内脏不适,但引人注目地是,它不影响进食动机、摄入食物或 CCK 信号处理的饱腹感效应。与单独使用任何一种治疗方法相比,联合使用 GDF15 和司美格鲁肽治疗产生了更大的食物摄入和体重抑制作用,而不会加重不适。
GDF15 和司美格鲁肽通过主要不同的过程减少食物摄入和体重,当联合使用时会产生更大的体重减轻和摄食抑制作用。